Fast Forward Therapeutic Innovation
July 18, 2024
Received orphan-drug designation from the FDA for our lead molecule, ABI-171, in the treatment of idiopathic pulmonary fibrosis (IPF).
July 23, 2023
Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK (1R43DK134232-01A1) for the development of new therapies for the treatment of liver diseases in collaboration with Ohio State University (Professor Richard Bruno)
May 5, 2019
Avanti Biosciences has been awarded the second phase of the fast-track SBIR grants from the NIA for its work on Alzheimer's Disease.
July 30, 2018
Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK for the development of new therapies for the treatment of Hyperinsulinemia Hyperammonemia Syndrome in collaboration with the Children's Hospital of Philadelphia (CHOP)
May 1, 2018
Avanti Biosciences open new operations in the JLAB San Diego.
August 15, 2017
Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s Disease
October 8, 2015